Cloudy Outlook for CSL's Vaccines Business in U.S. -- Market Talk
Dow Jones
Jun 23
0025 GMT - The outlook for CSL's vaccines business has turned a little less rosy. CSL's U.S. flu vaccine business makes up 8% of group revenue and 10% of group earnings. Bell Potter pares revenue growth forecasts for CSL's Seqirus unit following a wave of vaccine-related regulatory leadership changes in the U.S. Those changes include the recent overhaul of the CDC's vaccine advisory panel. "To be clear, we don't expect these regulatory changes to narrow CDC flu recommendations given their well-established safety record," says analyst Thomas Wakim. Still, it expects negative sentiment in the U.S. to persist in upcoming seasons. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 22, 2025 20:25 ET (00:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.